SOAT1 and acquired idiopathic inflammatory myopathy: The discovery of the role of interferon I and II in IIM (49) and the therapeutic effect of JAK/STAT inhibitor ruxolitinib in DM (9) brought new insights into the pathophysiology of IIM.